{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:22:01Z","timestamp":1780507321334,"version":"3.54.1"},"reference-count":3,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T00:00:00Z","timestamp":1606089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:p>Immunotherapy has changed the treatment landscape for cancer patients; however, immune-related adverse events, such as primary and secondary adrenal insufficiency, can be life threatening, with potential differences in population incidence. This letter to the editor reports a real-world experience of Hispanic\/Latino patients treated with immunotherapy and the incidence of adrenal insufficiency.<\/jats:p>","DOI":"10.1002\/onco.13588","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T12:48:40Z","timestamp":1604580520000},"page":"e191-e191","source":"Crossref","is-referenced-by-count":4,"title":["Primary Adrenal Insufficiency due to Immune Checkpoint Inhibitors: More Common than We Thought"],"prefix":"10.1093","volume":"26","author":[{"given":"Carlos","family":"Salinas","sequence":"first","affiliation":[{"name":"Centro de Investigaci\u00f3n Cl\u00ednica Bradford Hill, Santiago de Chile, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj","family":"Samtani","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Cl\u00ednica Bradford Hill, Santiago de Chile, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Burotto","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Cl\u00ednica Bradford Hill and Oncologia Medica, Clinica Universidad de los Andes, Santiago de Chile, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,23]]},"reference":[{"key":"2021122511542494000_onco13588-bib-0001","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1634\/theoncologist.2018-0470","article-title":"Endocrine-related adverse events related to immune checkpoint inhibitors: Proposed algorithms for management","volume":"25","author":"Del Rivero","year":"2020","journal-title":"The Oncologist"},{"key":"2021122511542494000_onco13588-bib-0002","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1210\/jc.2003-031854","article-title":"Polymorphisms in the cytotoxic T lymphocyte antigen-4 gene region confer susceptibility to Addison's disease","volume":"89","author":"Blomhoff","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122511542494000_onco13588-bib-0003","doi-asserted-by":"crossref","first-page":"5139","DOI":"10.1210\/jc.2009-1404","article-title":"Programmed death ligand 1 (PD-L1) gene variants contribute to autoimmune Addison's disease and Graves' disease susceptibility","volume":"94","author":"Mitchell","year":"2009","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13588","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13588","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/1\/e191\/41923511\/oncolo_26_1_e191.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/1\/e191\/41923511\/oncolo_26_1_e191.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T11:54:37Z","timestamp":1640433277000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/1\/e191\/6445336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":3,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,11,23]]},"published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13588","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,1]]},"published":{"date-parts":[[2020,11,23]]}}}